ArticleAnnals of clinical and translational neurology2026
Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy-Related Inflammation.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy-related inflammation (CAA-RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk.
methodsWe performed a retrospective cohort study of 36 patients with CAA-RI treated at the Cleveland Clinic from January 2020 to December 2024. Relapse was defined as recurrent vasogenic edema on MRI after corticosteroid treatment. Edema was classified as focal (1 lobar region), multifocal (2-3 regions), or diffuse (≥ 4 regions). Cause-specific Cox models and Gray's test evaluated predictors of relapse and mortality, and the effect of mycophenolate on relapse.
resultsAmong 36 patients (mean age 71.6 ± 8.2 years; 66.7% female), 11 (30.6%) relapsed, 9 (25.0%) died without having relapse, and 16 (44.4%) had neither event after a median prednisone taper of 4.5 months. 31 patients had follow-up data for time-to-event analyses, with a median follow-up time of 18.7 months. Cumulative relapse rates were 22.4%, 26.3%, and 44.0% at 6, 12, and 24 months, respectively. Diffuse edema strongly predicted relapse (hazard ratio [HR] = 12.26; 95% confidence interval [CI] = 1.95-76.94; p = 0.007). Mycophenolate was used in 11 patients; relapse occurred in 18.2% versus 30.0% without mycophenolate treatment. Initiation of mycophenolate at steroid taper in high-relapse-risk patients was associated with a statistically nonsignificant reduction in relapse risk (HR = 0.36; 95% CI = 0.07-1.09, p = 0.231).
interpretationRelapse in CAA-RI is common and extends beyond the early post-treatment phase. Diffuse edema on baseline MRI strongly predicts recurrence, enabling effective risk stratification. Mycophenolate shows promise as a steroid-sparing therapy for preventing relapse in high-risk patients and merits prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.